Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

45.41
-0.2700-0.59%
Post-market: 45.29-0.1200-0.26%19:20 EST
Volume:2.70M
Turnover:122.44M
Market Cap:26.48B
PE:25.49
High:45.68
Open:45.59
Low:44.94
Close:45.68
52wk High:47.86
52wk Low:29.66
Shares:583.17M
Float Shares:379.85M
Volume Ratio:0.67
T/O Rate:0.71%
Dividend:0.88
Dividend Rate:1.94%
EPS(TTM):1.78
EPS(LYR):1.78
ROE:13.20%
ROA:5.15%
PB:4.09
PE(LYR):25.49

Loading ...

How Investors Are Reacting To Royalty Pharma (RPRX) Expanding Oncology Royalties With Nuvalent Deal

Simply Wall St.
·
Dec 17, 2025

Royalty Pharma - Buys Low-Single Digit Royalty on Neladalkib and Zidesamtinib

THOMSON REUTERS
·
Dec 16, 2025

Royalty Pharma - Royalty Duration for Both Therapies Extends Through 2041 to 2042

THOMSON REUTERS
·
Dec 16, 2025

Royalty Pharma (RPRX): Revisiting Valuation After Fresh Analyst Upgrades and Strengthening Buy-Side Consensus

Simply Wall St.
·
Dec 15, 2025

Royalty Pharma : TD Cowen Raises Target Price to $45 From $42

THOMSON REUTERS
·
Dec 11, 2025

EVP, Investments & CLO George W. Lloyd Reports Disposal of Royalty Pharma plc Common Shares

Reuters
·
Dec 06, 2025

Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start

Benzinga_recent_news
·
Dec 06, 2025

Denali Therapeutics, Royalty Pharma Enter $275 Million Royalty Funding Agreement for Hunter Syndrome Treatment

Dow Jones
·
Dec 04, 2025

Denali Therapeutics Inc - Royalty Pharma to Receive 9.25% Royalty on Worldwide Sales of Tividenofusp Alfa From Denali

THOMSON REUTERS
·
Dec 04, 2025

Royalty Pharma EVP Marshall Urist Reports Sale of Common Shares

Reuters
·
Dec 04, 2025

Will Raised 2025 Guidance and CFO Share Sale Shift Royalty Pharma's (RPRX) Growth Narrative?

Simply Wall St.
·
Nov 29, 2025

Royalty Pharma CFO Terrance P. Coyne Reports Sale of Common Shares

Reuters
·
Nov 27, 2025

Royalty Pharma to Present at Citi and Evercore Healthcare Investor Conferences

Reuters
·
Nov 26, 2025

Royalty Pharma EVP George W. Lloyd Reports Sale of Common Shares

Reuters
·
Nov 22, 2025

Royalty Pharma plc Publishes Transcript of Q3 2025 Earnings Call

Reuters
·
Nov 11, 2025

A Look at Royalty Pharma’s (RPRX) Valuation Following Upgraded Guidance and Buybacks

Simply Wall St.
·
Nov 07, 2025

Stock Track | Royalty Pharma Soars 5.02% on Strong Q3 Results and Raised Guidance

Stock Track
·
Nov 05, 2025

Royalty Pharma Q3 Portfolio Receipts up 11%, guidance raised

Reuters
·
Nov 05, 2025

Royalty Pharma Q3 Adj. EPS $1.17 Beats $1.04 Estimate, Sales $609.000M Miss $739.257M Estimate

Benzinga
·
Nov 05, 2025

Royalty Pharma Q3 Adjusted Ebitda USD 779 Million

THOMSON REUTERS
·
Nov 05, 2025